Real-world outcomes of trastuzumab deruxtecan as second- or further-line treatment in patients with HER2-mutant metastatic non-small cell lung cancer: a retrospective study
Year: 2025
Type: article
Study design: Observational Study
Abstract: Background: Real-world data on the application of trastuzumab deruxtecan (T-DXd) in human epidermal growth factor receptor 2 (HER2)-mutant non-small cell lung cancer (NSCLC) are scarce. This study observed the effectiveness and safety of T-DXd for the treatment of Chinese patients with HER2-mutant advanced NSCLC in the real-world setting. Methods: This retrospective study was conducted at two centers in China. Clinical data were reviewed in patients who received T-DXd treatment. The primary outcomes were progression-free survival (PFS) and objective response rate (ORR). Results: Between April 2023 and January 2025, 35 patients were included. All patients had stage IV lung adenocarcinoma. Median age was 58 years (range, 33–87 years), and 18 (51.4%) patients were female. All patients received T-DXd as second- or further-line treatment. Most patients [24 (68.6%)] had HER2 exon 20 mutations. With a median follow-up of 9.7 months (range, 2.0–22.1 months), the median PFS was 7.85 months [95% confidence interval (CI): 6.64–15.05]. ORR was 51.4% (95% CI: 34.0–68.6%). Patients with previous anti-angiogenic therapy (n=11) had numerically worse prognosis (median PFS, 6.37 months; ORR, 36.4%). Elderly patients (n=10) achieved PFS benefit (median, 7.18 months) and ORR (60.0%) similar to the total population. Adverse events (AEs) were reported in 23 (65.7%) patients, with the most common being fatigue [14 (40.0%)]. No grade ≥3 AEs occurred. Conclusions: This study firstly supplements real-world evidence on T-DXd treatment in Chinese patients with previously treated HER2-mutant advanced NSCLC. The results preliminarily showed the favorable antitumor activity and acceptable safety profile of T-DXd in clinical practice.
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7117582277